Newsroom

Download PDF – Final OS Hazard Ratio Improves to 0.97 – – Company to Host Conference Call Today at 8:30 am Eastern Time – BOSTON–(BUSINESS WIRE)–May 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced the presentation of results from the final analysis of overall survival (OS) in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular

Download PDF BOSTON–(BUSINESS WIRE)–May 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s (LSE/STO/NYSE: AZN) human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular

Download PDF BOSTON–(BUSINESS WIRE)–May 27, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, the location of its 2020 Annual Meeting

Download PDF BOSTON–(BUSINESS WIRE)–Apr. 30, 2020– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. “Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (R/R RCC)

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 29, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma, will be presented at the upcoming American Society of Clinical Oncology (ASCO)

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 31, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). “NDA submission is a distinguishing

Download PDF CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Mar. 27, 2020– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. “The coming months will be an important period for AVEO, with filing of a New Drug Application (NDA) for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC) planned for